Intelence Now for Kids Ages 6 and Older
The HIV drug Intelence (etravirine) received approval from the Food and Drug Administration (FDA) for use by children ages six to 18 weighing at least 35 pounds, who have previous anti-HIV treatment experience. This includes children whose virus has developed drug resistance to the same class of medications as Intelence (non-nucleoside reverse transcriptase inhibitors, or NNRTIs). Sustiva and Viramune are the NNRTIs previously available for pediatric use. A new scored 25 mg tablet of Intelence is now available for pediatrics.
For more information about the drug, go to www.positivelyaware.com/intelence.
Got a comment on this article? Write to us at firstname.lastname@example.org.
Intelence (Etravirine): Pediatric Dosing Recommendations and New Scored 25 mg Tablet for Pediatric Dosing
This article was provided by Positively Aware. It is a part of the publication Positively Aware. Visit Positively Aware's website to find out more about the publication.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)